Skip to content
Clinical Trials – home

Find therapies in clinical trials near you – page 21

recruiting
3 987
countries
28
conditions
2 109

775 trials match your criteria

Study on the Effectiveness of Oxygen for Patients with Intermediate-Risk Acute Pulmonary Embolism

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Oxygen

Study on the Safety and Effects of Divarasib with Pembrolizumab and a Drug Combination for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with KRAS G12C Mutation

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Budesonide

Prostate cancer

Recruiting

Study on Darolutamide and Triptorelin for Patients with Localized High-Risk Prostate Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Darolutamide

Breast cancer+2

Recruiting

Study on Pembrolizumab and Paclitaxel for Early Triple-Negative Breast Cancer in Patients with High Tumor-Infiltrating Lymphocytes

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Paclitaxel

Long-Term Safety Study of ACP-204 for Adults with Alzheimer's Disease Psychosis

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:ACP-204 tartrate

Study of talazoparib and enzalutamide combination treatment for patients with metastatic prostate cancer who previously received abiraterone

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Enzalutamide

Comparison of belantamab mafodotin, bortezomib and dexamethasone versus daratumumab, bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Belantamab Mafodotin

Myelofibrosis+1

Recruiting

Study on the Effectiveness and Safety of Selinexor for Patients with Myelofibrosis and Moderate Thrombocytopenia Who Have Not Used JAK Inhibitors

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Aprepitant

Study on Donepezil for Mild Cognitive Impairment in Parkinson's Disease Patients

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Donepezil Hydrochloride
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Mavorixafor

Study of RMC-6291 and Pembrolizumab with or without Chemotherapy for Patients with Advanced KRAS G12C Mutated Lung Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Finerenone
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.